Enregistrement :
22
de
39
(2018-01-08
à
2018-08-01)
Politique ou Programme
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Patented Medicine Prices Review Board (PMPRB)consultation on the proposed modernization of the Compendium of Policies, Guidelines and Procedures
The Department of Innovation, Science and Economic Development consultation on the new Innovation Agenda: policy or program initiatives to support life science Research and Development conducted in Canada
Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
Health Canada's Consultation on fee proposal for drugs and medical devices
The international trade negotiations under the North American Free Trade Agreement as it relates to potential legislative or regulatory changes of Canada's intellectual property regime for pharmaceutical products (Patent Act); Regulatory harmonization; the outdated supply chain regulations; pricing; cross-border trade; and confidential business information.
Politique ou Programme, Règlement
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.
Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries
Proposition législative, Projet de loi ou résolution, Règlement
Patent Act as it relates to the implementation of the Comprehensive Economic Trade Agreement (CETA) and its Intellectual property protection provisions.
Règlement
Health Canada's consultation on the future of Regulation of Self-Care Products
Proposed modernization of the Patented Medicines Prices Review Board (PMPRB) Regulations in the consultation document “Protecting Canadians from Excessive Drug Prices”
Subvention, Contribution ou autre avantage financier
National Immunization Strategy. Advocacy to seek continued funding in vaccines.